heterolog
neutral
serum
antiserum
consist
neutral
antibodi
produc
mainli
hors
sheep
effect
use
centuri
antiserum
born
golden
age
microbiolog
von
beher
kitasato
show
serum
diphtheriainfect
anim
confer
immun
diseas
naiv
anim
four
year
later
antiserum
use
human
point
method
alway
demonstr
highli
effect
treatment
infect
envenom
howev
antiserum
good
outcom
respect
safeti
initi
applic
caus
mani
lifethreaten
side
reaction
current
mani
applic
heterolog
serum
replac
drug
antibiot
homolog
serum
howev
case
envenom
snakebit
scorpion
arachnid
antiserum
remain
effect
treatment
recent
applic
antiserum
demonstr
good
safeti
profil
patient
mild
advers
reaction
sever
reaction
weak
antiserum
like
biolog
product
induc
reactiv
patient
gener
antibodi
antiserum
weak
caus
effect
safeti
compromis
success
treatment
word
heterolog
serum
use
first
decad
twentieth
centuri
advent
antibiot
heterolog
serum
best
treatment
choic
infecti
diseas
mani
diseas
treat
heterolog
serum
high
effect
variabl
safeti
exampl
neisseria
meningitidi
epidem
new
york
citi
control
heterolog
specif
serum
decreas
mortal
onethird
later
twentieth
centuri
antiserum
began
displac
drug
better
safeti
profil
antibiot
vaccin
howev
treatment
envenom
tetanu
diphtheria
rabi
antiserum
seen
continu
success
use
current
treatment
tetanu
diphtheria
chang
antiserum
homolog
serum
obtain
healthi
human
donor
mani
countri
antiserum
remain
option
treatment
case
snakebit
envenom
antiserum
effect
treatment
mani
emerg
diseas
ebola
viru
riskbenefit
equat
use
antiserum
appear
highli
tilt
toward
benefit
addit
necessari
use
antiserum
surviv
patient
demonstr
immun
first
contact
anoth
benefit
low
product
cost
make
type
drug
afford
countri
unfortun
vaccin
monoclon
homolog
antibodi
becam
popular
solut
antiserum
less
success
mani
emerg
diseas
futur
threat
howev
antiserum
could
chanc
dixit
cowork
propos
antiserum
possibl
solut
avian
influenza
merscov
viral
hemorrhag
fever
heterolog
serum
also
advantag
made
use
recombin
protein
avoid
risk
manipul
infect
pathogen
product
stage
antiserum
old
drug
centuri
use
perhap
pharmaceut
compani
scientist
consid
type
drug
obsolet
opt
new
gener
antibodi
monoclon
human
howev
antiserum
still
advantag
monoclon
antibodi
shorter
product
develop
time
reduc
cost
develop
product
summari
antiserum
good
option
treatment
emerg
infecti
diseas
drug
unavail
author
confirm
sole
contributor
work
approv
public
